Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

A long-amplicon quantitative PCR assay with propidium monoazide to enumerate viable Listeria monocytogenes after heat and desiccation treatments.

Kragh ML, Thykier M, Truelstrup Hansen L.

Food Microbiol. 2020 Apr;86:103310. doi: 10.1016/j.fm.2019.103310. Epub 2019 Aug 23.

PMID:
31703859
2.

Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.

Alifrangis L, Schoemaker R, Skartved NJ, Hald R, Montagut C, Kopetz S, Tabernero J, Kragh M, Wade JR.

J Pharmacokinet Pharmacodyn. 2019 Nov 2. doi: 10.1007/s10928-019-09663-2. [Epub ahead of print]

PMID:
31679083
3.

Automatic grading of human blastocysts from time-lapse imaging.

Kragh MF, Rimestad J, Berntsen J, Karstoft H.

Comput Biol Med. 2019 Oct 15;115:103494. doi: 10.1016/j.compbiomed.2019.103494. [Epub ahead of print]

4.

HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.

Sampera A, Sánchez-Martín FJ, Arpí O, Visa L, Iglesias M, Menéndez S, Gaye É, Dalmases A, Clavé S, Gelabert-Baldrich M, Poulsen TT, Kragh M, Bellosillo B, Albanell J, Rovira A, Montagut C.

Mol Cancer Ther. 2019 Nov;18(11):2135-2145. doi: 10.1158/1535-7163.MCT-19-0455. Epub 2019 Sep 4.

PMID:
31484705
5.

Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.

Gjetting T, Gad M, Fröhlich C, Lindsted T, Melander MC, Bhatia VK, Grandal MM, Dietrich N, Uhlenbrock F, Galler GR, Strandh M, Lantto J, Bouquin T, Horak ID, Kragh M, Pedersen MW, Koefoed K.

MAbs. 2019 May/Jun;11(4):666-680. doi: 10.1080/19420862.2019.1596514. Epub 2019 May 3.

6.

[Psychiatry and circadian rhythms].

Martiny K, Volf C, Svendsen SD, Kragh M, Madsen HØ, Hageman I.

Ugeskr Laeger. 2018 Sep 3;180(36). pii: V04180278. Review. Danish.

PMID:
30348255
7.

The impact of modified mania assessment scale (MAS-M) implementation on the use of mechanical restraint in psychiatric units.

Odgaard AS, Kragh M, Roj Larsen E.

Nord J Psychiatry. 2018 Nov;72(8):549-555. doi: 10.1080/08039488.2018.1490816. Epub 2018 Oct 23.

PMID:
30348037
8.

Predictors of response to combined wake and light therapy in treatment-resistant inpatients with depression.

Kragh M, Larsen ER, Martiny K, Møller DN, Wihlborg CS, Lindhardt T, Videbech P.

Chronobiol Int. 2018 Sep;35(9):1209-1220. doi: 10.1080/07420528.2018.1468341. Epub 2018 May 11.

PMID:
29750548
9.

Neonates colonized with pathogenic bacteria in the airways have a low-grade systemic inflammation.

Rahman Fink N, Chawes BL, Thorsen J, Stokholm J, Krogfelt KA, Schjørring S, Kragh M, Bønnelykke K, Brix S, Bisgaard H.

Allergy. 2018 Nov;73(11):2150-2159. doi: 10.1111/all.13461. Epub 2018 Oct 11.

PMID:
29672858
10.

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.

Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD.

J Neurooncol. 2018 Jul;138(3):489-498. doi: 10.1007/s11060-018-2832-6. Epub 2018 Mar 21.

11.

Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015.

Pollmann SE, Calvert VS, Rao S, Boca SM, Madhavan S, Horak ID, Kjaer A, Petricoin EF, Kragh M, Poulsen TT.

Mol Cancer Ther. 2018 Jun;17(6):1259-1270. doi: 10.1158/1535-7163.MCT-17-0787. Epub 2018 Mar 15.

12.

Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.

Kim HJ, Kang SK, Kwon WS, Kim TS, Jeong I, Jeung HC, Kragh M, Horak ID, Chung HC, Rha SY.

Int J Cancer. 2018 Jul 1;143(1):151-159. doi: 10.1002/ijc.31304. Epub 2018 Feb 23.

13.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J.

JAMA Oncol. 2018 Apr 12;4(4):e175245. doi: 10.1001/jamaoncol.2017.5245. Epub 2018 Apr 12. Erratum in: JAMA Oncol. 2019 May 1;5(5):745.

14.

FieldSAFE: Dataset for Obstacle Detection in Agriculture.

Kragh MF, Christiansen P, Laursen MS, Larsen M, Steen KA, Green O, Karstoft H, Jørgensen RN.

Sensors (Basel). 2017 Nov 9;17(11). pii: E2579. doi: 10.3390/s17112579.

15.

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.

Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx065.

16.

Patientś experiences of patient education on psychiatric inpatient wards; a systematic review.

Kristiansen ST, Videbech P, Kragh M, Thisted CN, Bjerrum MB.

Patient Educ Couns. 2018 Mar;101(3):389-398. doi: 10.1016/j.pec.2017.09.005. Epub 2017 Sep 12.

PMID:
28918106
17.

Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms.

Grandal MM, Havrylov S, Poulsen TT, Koefoed K, Dahlman A, Galler GR, Conrotto P, Collins S, Eriksen KW, Kaufman D, Woude GFV, Jacobsen HJ, Horak ID, Kragh M, Lantto J, Bouquin T, Park M, Pedersen MW.

Mol Cancer Ther. 2017 Dec;16(12):2780-2791. doi: 10.1158/1535-7163.MCT-17-0374. Epub 2017 Aug 11.

18.

Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.

Poulsen TT, Grandal MM, Skartved NJØ, Hald R, Alifrangis L, Koefoed K, Lindsted T, Fröhlich C, Pollmann SE, Eriksen KW, Dahlman A, Jacobsen HJ, Bouquin T, Pedersen MW, Horak ID, Lantto J, Kragh M.

Clin Cancer Res. 2017 Oct 1;23(19):5923-5935. doi: 10.1158/1078-0432.CCR-17-0782. Epub 2017 Jul 5.

19.

Wake and light therapy for moderate-to-severe depression - a randomized controlled trial.

Kragh M, Martiny K, Videbech P, Møller DN, Wihlborg CS, Lindhardt T, Larsen ER.

Acta Psychiatr Scand. 2017 Dec;136(6):559-570. doi: 10.1111/acps.12741. Epub 2017 Apr 19.

PMID:
28422269
20.

A safflower oil based high-fat/high-sucrose diet modulates the gut microbiota and liver phospholipid profiles associated with early glucose intolerance in the absence of tissue inflammation.

Danneskiold-Samsøe NB, Andersen D, Radulescu ID, Normann-Hansen A, Brejnrod A, Kragh M, Madsen T, Nielsen C, Josefsen K, Fretté X, Fjaere E, Madsen L, Hellgren LI, Brix S, Kristiansen K.

Mol Nutr Food Res. 2017 May;61(5). doi: 10.1002/mnfr.201600528. Epub 2017 Feb 22.

PMID:
28012235
21.

Experiences of wake and light therapy in patients with depression: A qualitative study.

Kragh M, Møller DN, Wihlborg CS, Martiny K, Larsen ER, Videbech P, Lindhardt T.

Int J Ment Health Nurs. 2017 Apr;26(2):170-180. doi: 10.1111/inm.12264. Epub 2016 Nov 2.

PMID:
27804203
22.

Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.

Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL.

Mol Cancer Ther. 2016 Sep;15(9):2175-86. doi: 10.1158/1535-7163.MCT-16-0012. Epub 2016 Jul 15.

23.

Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.

Ellebaek S, Brix S, Grandal M, Lantto J, Horak ID, Kragh M, Poulsen TT.

Int J Cancer. 2016 Nov 1;139(9):2095-105. doi: 10.1002/ijc.30242. Epub 2016 Jul 19.

24.

Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.

Kjær I, Lindsted T, Fröhlich C, Olsen JV, Horak ID, Kragh M, Pedersen MW.

Mol Cancer Ther. 2016 Jul;15(7):1614-26. doi: 10.1158/1535-7163.MCT-15-0565. Epub 2016 May 11.

25.

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.

Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C.

Clin Cancer Res. 2016 Jul 1;22(13):3260-7. doi: 10.1158/1078-0432.CCR-15-2400. Epub 2016 Feb 17.

26.

Divergent response profile in activated cord blood T cells from first-born child implies birth-order-associated in utero immune programming.

Kragh M, Larsen JM, Thysen AH, Rasmussen MA, Wolsk HM, Bisgaard H, Brix S.

Allergy. 2016 Mar;71(3):323-32. doi: 10.1111/all.12799. Epub 2015 Dec 2.

PMID:
26505887
27.

In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.

Nielsen CH, Jensen MM, Kristensen LK, Dahlman A, Fröhlich C, Jacobsen HJ, Poulsen TT, Lantto J, Horak ID, Kragh M, Kjaer A.

Oncotarget. 2015 Nov 10;6(35):37486-99. doi: 10.18632/oncotarget.6060.

28.

Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.

Francis DM, Huang S, Armstrong EA, Werner LR, Hullett C, Li C, Morris ZS, Swick AD, Kragh M, Lantto J, Kimple RJ, Harari PM.

Clin Cancer Res. 2016 Feb 1;22(3):633-43. doi: 10.1158/1078-0432.CCR-15-1664. Epub 2015 Sep 29.

29.

The genomic landscape of response to EGFR blockade in colorectal cancer.

Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L, Velculescu VE.

Nature. 2015 Oct 8;526(7572):263-7. doi: 10.1038/nature14969. Epub 2015 Sep 30.

30.

[Wake therapy for major depression].

Kragh M, Videbech P.

Ugeskr Laeger. 2015 Sep 7;177(37):V03150260. Review. Danish.

PMID:
26376242
31.

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J.

Cancer Discov. 2015 Jun;5(6):598-609. doi: 10.1158/2159-8290.CD-14-1432. Epub 2015 May 11.

32.

Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity.

Jacobsen HJ, Poulsen TT, Dahlman A, Kjær I, Koefoed K, Sen JW, Weilguny D, Bjerregaard B, Andersen CR, Horak ID, Pedersen MW, Kragh M, Lantto J.

Clin Cancer Res. 2015 Sep 15;21(18):4110-22. doi: 10.1158/1078-0432.CCR-14-3312. Epub 2015 Apr 23.

33.

Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance.

Pedersen MW, Jacobsen HJ, Koefoed K, Dahlman A, Kjær I, Poulsen TT, Meijer PJ, Nielsen LS, Horak ID, Lantto J, Kragh M.

Mol Cancer Ther. 2015 Mar;14(3):669-80. doi: 10.1158/1535-7163.MCT-14-0697. Epub 2015 Jan 22.

34.

Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.

Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, Wheeler DL.

Neoplasia. 2013 Oct;15(10):1196-206.

35.

Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.

Huang S, Peet CR, Saker J, Li C, Armstrong EA, Kragh M, Pedersen MW, Harari PM.

Mol Cancer Ther. 2013 Dec;12(12):2772-81. doi: 10.1158/1535-7163.MCT-13-0587. Epub 2013 Oct 15.

36.

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.

Koefoed K, Steinaa L, Søderberg JN, Kjær I, Jacobsen HJ, Meijer PJ, Haurum JS, Jensen A, Kragh M, Andersen PS, Pedersen MW.

MAbs. 2011 Nov-Dec;3(6):584-95. doi: 10.4161/mabs.3.6.17955. Epub 2011 Nov 1.

37.

Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.

Skartved NJ, Jacobsen HJ, Pedersen MW, Jensen PF, Sen JW, Jørgensen TK, Hey A, Kragh M.

Clin Cancer Res. 2011 Sep 15;17(18):5962-72. doi: 10.1158/1078-0432.CCR-11-1209. Epub 2011 Aug 8.

38.

Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M.

Cancer Res. 2010 Jan 15;70(2):588-97. doi: 10.1158/0008-5472.CAN-09-1417. Epub 2010 Jan 12.

39.

The beta-glucosidases responsible for bioactivation of hydroxynitrile glucosides in Lotus japonicus.

Morant AV, Bjarnholt N, Kragh ME, Kjaergaard CH, Jørgensen K, Paquette SM, Piotrowski M, Imberty A, Olsen CE, Møller BL, Bak S.

Plant Physiol. 2008 Jul;147(3):1072-91. doi: 10.1104/pp.107.109512. Epub 2008 May 8. Erratum in: Plant Physiol. 2010 Apr;152(4):2269.

40.

Interleukin 21: combination strategies for cancer therapy.

Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV.

Nat Rev Drug Discov. 2008 Mar;7(3):231-40. doi: 10.1038/nrd2482. Review. Erratum in: Nat Rev Drug Discov. 2008 Mar;7(3):272.

PMID:
18259184
41.

Spectroscopic studies of perturbed T1 Cu sites in the multicopper oxidases Saccharomyces cerevisiae Fet3p and Rhus vernicifera laccase: allosteric coupling between the T1 and trinuclear Cu sites.

Augustine AJ, Kragh ME, Sarangi R, Fujii S, Liboiron BD, Stoj CS, Kosman DJ, Hodgson KO, Hedman B, Solomon EI.

Biochemistry. 2008 Feb 19;47(7):2036-45. doi: 10.1021/bi7020052. Epub 2008 Jan 16.

PMID:
18197705
42.

Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.

Søndergaard H, Frederiksen KS, Thygesen P, Galsgaard ED, Skak K, Kristjansen PE, Odum N, Kragh M.

Cancer Immunol Immunother. 2007 Sep;56(9):1417-28. Epub 2007 Feb 7.

PMID:
17285290
43.

Non-anti-coagulant heparins: a promising approach for prevention of tumor metastasis (review).

Kragh M, Loechel F.

Int J Oncol. 2005 Oct;27(4):1159-67. Review.

PMID:
16142335
44.

Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth.

Kragh M, Binderup L, Vig Hjarnaa PJ, Bramm E, Johansen KB, Frimundt Petersen C.

Oncol Rep. 2005 Jul;14(1):99-104.

PMID:
15944775
45.

A versatile in vivo chamber angiogenesis assay for measuring anti-angiogenic activity in mice.

Kragh M, Hjarnaa PJ, Bramm E, Binderup L.

Oncol Rep. 2004 Feb;11(2):303-7.

PMID:
14719059
46.

In vivo chamber angiogenesis assay: an optimized Matrigel plug assay for fast assessment of anti-angiogenic activity.

Kragh M, Hjarnaa PJ, Bramm E, Kristjansen PE, Rygaard J, Binderup L.

Int J Oncol. 2003 Feb;22(2):305-11.

PMID:
12527927
47.
48.

Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma.

Kragh M, Quistorff B, Tenan M, Van Meir EG, Kristjansen PE.

Cancer Res. 2002 Feb 15;62(4):1191-5.

49.

Quantitative estimates of vascularity in solid tumors by non-invasive near-infrared spectroscopy.

Kragh M, Quistorff B, Lund EL, Kristjansen PE.

Neoplasia. 2001 Jul-Aug;3(4):324-30.

50.

Supplemental Content

Support Center